TGA issues alert after person was hospitalised after believing they were taking experimental weight loss drug retatrutide
Get our breaking news email, free app or daily news podcast
A patient who tore their oesophagus after taking a counterfeit version of an experimental weight loss drug has prompted Australia’s medicines regulator to warn of serious risks of such products.
The concern relates to retatrutide, a type of drug known as a peptide. Retatrutide has not been approved by the Therapeutic Goods Administration (TGA) or regulators overseas, and it cannot be legally prescribed or sold in Australia.
Continue reading...
